Amycretin

Early human Weight Loss & Metabolism 3 sources

Amycretin is a novel, unimolecular co-agonist that synergistically activates both GLP-1 and amylin receptors. Early clinical research shows it can significantly reduce body weight, with trials demonstrating up to 24% weight loss over 36 weeks.

01Dosing reference

Amount

Up to 60 mg (in clinical trials)

Frequency

Once weekly (subcutaneous) or once daily (oral)

Cycle

Continuous use in clinical trials (e.g., 36 weeks)

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GLP-1 and Amylin Receptor Co-agonism

The single molecule binds to and activates both GLP-1 and amylin receptors simultaneously.

Synergistic Satiety and Gastric Emptying

Dual agonism engages hindbrain satiety centers and delays gastric emptying, significantly enhancing feelings of fullness.

Enhanced Weight Loss

This combined action leads to profound reductions in body weight and improvements in metabolic parameters compared to single-receptor activation.

03Human evidence

Once-weekly subcutaneous amycretin up to 60 mg reduced body weight by 24% at 36 weeks compared to 1% with placebo.

Phase 1b/2a randomized, placebo-controlled study evaluating safety, tolerability, and effects on body weight.

Oral amycretin demonstrated safety, tolerability, and significant weight reduction properties.

First-in-human, phase 1, double-blind, randomized study supporting further investigation of its weight loss properties.

04Preclinical evidence

Mitigated diet-induced metabolic disorders, such as obesity, insulin resistance, and fatty liver.

Animal models of diet-induced obesity used to evaluate metabolic effects.

Demonstrated potent dual activation of both GLP-1 and amylin receptors.

In vitro receptor binding and activation assays.

05What is known vs. unknown

Reasonably established

Amycretin is a unimolecular dual agonist targeting both GLP-1 and amylin receptors.
It is being developed in both oral (once-daily) and subcutaneous (once-weekly) formulations.
Early clinical data shows weight loss of up to 24% over 36 weeks, making it highly competitive in the obesity medication landscape.
Its safety and tolerability profile is consistent with other GLP-1 and amylin agonists, primarily involving gastrointestinal side effects.

Unknowns & limits

Long-term safety and cardiovascular outcomes are not yet established, as it is still in early-to-mid stage clinical trials.
The exact long-term tolerability of the dual agonism approach compared to GLP-1 mono-agonists remains to be fully elucidated in larger populations.

06Safety & regulatory context

Regulatory statusAmycretin is currently an investigational drug and is not FDA-approved. Its safety profile in early trials is consistent with other incretin-based therapies, with the most common side effects being gastrointestinal in nature, such as nausea, vomiting, and diarrhea. Contraindications are likely to mirror those of other GLP-1 receptor agonists, including a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

07Compared with Semaglutide

Amycretin vs. Semaglutide

Key difference

Semaglutide is a GLP-1 receptor mono-agonist, whereas amycretin is a unimolecular dual agonist that activates both GLP-1 and amylin receptors.

When researchers discuss each

Semaglutide is discussed as the established standard of care for obesity and type 2 diabetes, while amycretin is discussed as a next-generation therapy with potentially greater weight loss efficacy due to its dual mechanism.

08Glossary

Unimolecular co-agonist

A single molecule designed to bind to and activate two different types of receptors.

Amylin

A peptide hormone co-secreted with insulin that plays a role in glycemic regulation by slowing gastric emptying and promoting satiety.

GLP-1 (Glucagon-like peptide-1)

An incretin hormone that stimulates insulin secretion, suppresses glucagon secretion, and slows gastric emptying.

09Knowledge check

Q1What two receptors does amycretin target?

Q2In early clinical trials, what was the approximate weight loss observed with subcutaneous amycretin over 36 weeks?

Q3Which limitation of Amycretin’s current evidence is explicitly noted in the dossier?

Q4When researchers compare Amycretin with semaglutide, how does the dossier say they are positioned relative to one another?

Q5Which statement best reflects Amycretin’s regulatory status and the most commonly reported side effects in the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.